Curaleaf's Takeover Bid for Aurora Cannabis: Offer Terms, Timeline and Impact

Executive summary

Curaleaf raised its offer for Aurora Cannabis on October 5, 2026, lifting the total implied consideration by 25% to US$5.00 per Aurora share, an 86% premium to Aurora's unaffected share price. The move turns a bid between one of the largest U.S. multi-state operators (MSOs) and one of Canada's best-known licensed producers into a live contest for control of a global medical cannabis platform.

Cannabis Business Times reported the enhanced offer. Working backward from the reported figures, the previous implied value was about US$4.00 per share, and the unaffected price was roughly US$2.69. Those two figures are our arithmetic, not company disclosures.

The deal matters because it would be one of the first large cross-border combinations of a plant-touching U.S. operator with a Nasdaq-listed Canadian licensed producer. It would test three regimes at once: Canadian take-over bid and corporate law, Health Canada licensing under the Cannabis Act, and U.S. exchange rules that keep federally illegal cannabis businesses off Nasdaq and the NYSE.

This page is the canonical reference for the bid. It separates what is confirmed from what is analysis, and it will carry dated updates as Aurora's board, shareholders, regulators and exchanges respond. Terms we could not verify from the triggering report, including the cash-versus-stock mix, the deal structure, any financing and the exact timetable, are not stated as fact here.

Why this matters

The bid combines the U.S. market's scale with Canada's federally legal infrastructure and Europe's growing medical import market, at a time when U.S. federal reform is still unsettled.

Stakeholders

• Aurora shareholders face a decision on a premium bid after years of dilution, impairments and share consolidations.
• Curaleaf shareholders are being asked to back a large, expensive transaction while U.S. operators still pay the tax burden of 280E.
• Patients in Germany, the UK, Poland, Australia and Canada depend on Aurora's medical supply chain. A change of control could affect product continuity and pricing.
• Lenders, exchanges and regulators must decide how to treat a combined company with both Canadian-legal and U.S. state-legal operations.

Scale and dollars

The headline number is the US$5.00 per share implied value. On the 86% premium, the offer sits well above where Aurora traded before the bid became public. A 25% bump is a large single step in a take-over contest. It signals that Curaleaf either met resistance, anticipated a rival, or wanted to pre-empt a "just say no" response from Aurora's board.

The strategic read

Our read is that three assets drive the logic:

1. Federally legal cultivation and processing. Aurora operates under Canada's Cannabis Act, which U.S. operators cannot replicate while cannabis remains in Schedule I under 21 U.S.C. § 812.
2. International medical channels. Aurora has built a significant medical business in Germany and other markets. Curaleaf has its own European platform and could use scale in sourcing.
3. Capital markets access. A Nasdaq-listed counterparty is the kind of listing U.S. plant-touching MSOs cannot hold. How the combined entity is structured is the central unanswered question.

Background and history

Aurora and Curaleaf grew from opposite sides of the border: Aurora through Canadian federal legalization and aggressive acquisitions, Curaleaf through U.S. state licenses and roll-ups.

Aurora's origins and the Canadian build-out (2006–2018)

Aurora Cannabis traces its corporate roots to 2006 and became a licensed producer under Canada's earlier medical cannabis regimes. It was headquartered in Edmonton, Alberta, and built large-scale production capacity ahead of federal adult-use legalization.

In early 2018 Aurora acquired CanniMed Therapeutics in a closely contested bid. In mid-2018 it acquired MedReleaf in a transaction announced at roughly C$3.2 billion. Those deals made it one of the largest cannabis companies in the world by market value at the time.

Canadian legalization (October 17, 2018)

The Cannabis Act took effect on October 17, 2018, making Canada the first G7 country to legalize adult-use cannabis nationally. The Act created the licensing framework under which Aurora and its peers operate, with Health Canada as regulator.

The post-2019 reset

Canadian licensed producers overbuilt for demand that arrived more slowly than forecast. Aurora took large impairments, closed or idled facilities, replaced leadership in 2020 with Miguel Martin as chief executive, and carried out multiple share consolidations. Its strategy shifted toward higher-margin medical cannabis, especially in international markets, and toward consumer brands with stronger positions in premium flower.

Curaleaf's roll-up (2010s–2021)

Curaleaf began as a Massachusetts-based operator and grew into the largest U.S. MSO by revenue under executive chairman Boris Jordan. Key steps included:

• Listing on the Canadian Securities Exchange in 2018, with U.S. over-the-counter trading under the symbol CURLF.
• The Select acquisition, which added a branded vape and concentrate business.
• The Grassroots acquisition, announced in 2020 and valued at roughly US$875 million, which added Illinois, Pennsylvania, Maryland, New Jersey and other footprints.
• European expansion through the EMMAC Life Sciences acquisition and a German and UK medical presence.

The listing problem

Because cannabis remains a Schedule I controlled substance under 21 U.S.C. § 812, plant-touching U.S. operators have been shut out of Nasdaq and the NYSE. Canadian exchanges also restricted listings tied to U.S. marijuana activity. U.S. MSOs therefore clustered on the CSE and OTC markets. Aurora, which does not hold U.S. plant-touching licenses, kept its U.S. exchange listing. That asymmetry is why this deal is difficult to structure.

Federal reform context (2022–2026)

The U.S. Department of Health and Human Services recommended